We use cookies to study and improve the user experience offered by the site. By continuing to browse the site you are agreeing to our cookie policy.

List of winners of the International Fellowship Josep Carreras - E.D Thomas

  • 1991-1992-1993: Dr. Catherine Verfaillie, University of Minnesota (USA). CML: purification of bening stem cells useful for autologous transplant and generation of autologous A-LAK suitable for post-transplant consolidation.
  • 1992-1993-1994: Dr. Alessandra Cesano, The Winstar Institute (USA). An in-vivo model of cell-mediated lyisi against acute lymphoblastic leukemia.
  • 1993-1994-1995: Dr. Ana Carrera, Fundación Severo Ochoa / Centro de Biología Molecular / Universidad Autónoma de Madrid (Spain). Study of the effects of pp56lck mutants with substrate specificity on cell transformation.
  • 1993-1994-1995: Dr. Robert S. Negrin, Standford University Hospital (USA). Biology of cytokine induced natural killer cells.
  • 1994-1995-1996: Dr. Bruce C. Clurman, Fred Hutchinson Cancer Research Center (USA). Targeted disruption of Aessential genes in lymphoma cells.
  • 1995-1996-1997: Dr. I. Sanchez-García, Instituto de Microbiología Bioquímica CSIC / Universidad de Salamanca (Spain). Gene therapy for the treatment of Philadelphia cromosome-positive leukaemia.
  • 1996-1997-1998: Dr. Martin Stattler, Dana-Farber Cancer Institute, Boston (USA). Role of Activationof Stat Proteins by BCR/ABL in the pathogenesis of chronic myeloid leukemia (CML).
  • 1997-1998-1999: Dr. Ralf Huss, Institute of Pathology, University of Munich (Germany). Mechanisms of differentiation, proliferation and cell clycle progression in hematopoietic stem cells: a model for leukemic transformation.
  • 1997-1998-1999: Dr. Mathew Fero, Fred Hutchinson Cancer Research Center, Seattle (USA). Tumor suppression by CDK Inhibitors.
  • 1998-1999-2000: Dr. Koichi Akashi, Stanford University School of Medicine (USA). Identification of Human Common Lymphoid Progenitor.
  • 1999-2000-2001: Dr. Francesco Galimi, The Salk Institute, La Jolla, California (USA). Role of Telomere Maintenance in Human Hematopoietic Stem Cells: A Gene Transfer Approach.
  • 2000-2001-2002: Dr. Claudia Huettner, Beth Israel Deaconess Medical Center - Harvard Institutes of Medicine (USA). Conditional transgenic models of BCR/ABL leukemia.
  • 2000-2001-2002: Dr. Soheil Meshinchi, Fred Hutchinson Cancer Research Center, Seattle (USA). Biologic and clinical significance of Flt3 internal tandem duplication in pediatric Acute Myeloid Leukemia.
  • 2000-2001-2002: Dr. Elena Tassi, Instituto Nazionale Tumori Milano (Italy). Molecular Mechanism involved in the resistance to BCR/ABL inhibition in neoplastic cells (renounced the scholarship that was subsequently awarded to Dr. Gumby).
  • 2000-2001-2002: Dra. Rosalyn Gumby, Instituto Nazionale Tumori Milano (Italy). Investigation of the Mechanisms of resistance to the BCR/ABL inhibitor STI571.
  • 2001-2002-2003: Dr. Homayoun Vaziri, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts (USA). Molecular determinants of cellular senescense and immortalization.
  • 2002-2003-2004: Dr. Emmanuelle Pessegue, Stanford University (USA). Towards a better understanding of molecular mechanisms of myeloid leukemia.
  • 2003-2004-2005: Dr. Alejandro Barbieri, Washington University School of Medicine (USA). Role of Ras interference 1 (rin) in acute and chronic myelogenous leukaemias.
  • 2004-2005-2006: Dr. Yukiko Yamashita, Stanford University (USA). The mechanisms that control stem cell fate between proliferation and differentiation by asymmetric stem cell division.
  • 2005-2006-2007: Dr. Golam Mohi, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston (USA). The Gab2/Shp2 Pathway in Human leukaemia.
  • 2006-2007-2008: Dr. Pablo Menéndez, Institute of Cancer Research- Chester Beatty Laboratories, London (UK). Developmental Impact of MLL-AF4 Leukaemic Fusion Gene on Human Stem Cell Fate.
  • 2007-2008-2009: Dr. Karl Novina, Dana Farber Cancer Institute, Boston (USA). Mouse modeling of Micro-RNA function in chronic lymphocytic leukemia.
  • 2008-2009-2010: Dr. Jean François Rual, Harvard Medical School - Dept. of Cell Biology, Boston (USA). Molecular and Genetic definition of the Notch signalling network, a major factor in T-ALL.
  • 2009-2010-2011: Dr. Hanna Cullup, Mater Medical Research Institute South Brisbane (Australia). Antibody-mediated dendritic cell depletion to attenuate GVHD and promote GVL.
  • 2010-2011-2012: Dr. Adlen Foudi, Harvard Medical School, Stem Cell Institute, Boston (USA). Role of Gfi-1 family of transcriptional repressors in normal hematopoiesis and leukaemia.
  • 2011-2012-2013: Dr. Robert S. Welner, Ph.D. Beth Israel Deaconess, Boston (USA). β-catenin maintains leukemic stem cells by suppressing transcription factors required for differentiation.
  • 2012-2013-2014: Dr. Pedro Pablo Medina, Kline Biology Laboratory, Yale University (USA). Micro-RNA-21 induced haematological malignancies.
  • 2013-2014-2015: Dr. Thomas Schmitt, Fred Hutchinson Cancer Research Center, Seattle (USA). Targeting Leukemia with Enhanced-Affinity TCR Gene Therapy.
Webpage updated 08/28/2017 12:37:40